Today: 4 March 2026
Subscribe
Browse Category

Stock Market 24 October 2025

Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next?

Theriva shares surged 92% intraday Oct. 15 after its VCN-01 therapy met primary endpoints in a Phase 2b pancreatic cancer trial, then fell back following a $4 million equity raise. Median survival in a two-dose subgroup reached 14.8 months versus 11.6 for chemo alone. The company held $12.1 million cash as of June 30, 2025, funding operations into early 2026. Expanded trial results will be presented at ESMO Oct. 20.
24 October 2025
·
The $350B Shake-Up: How AI Summaries Rewire Publisher Traffic

Alphabet Stock Skyrockets to Record High, Nears $3 Trillion on AI Boom & Earnings Hype

Alphabet Inc. hit a record near $260 per share on Oct. 24, pushing its market value to about $3.1 trillion. The stock rebounded after a volatile week, buoyed by a breakthrough quantum computing announcement and a major cloud deal with Anthropic. Analysts raised price targets, with several now above $290. Alphabet reports Q3 earnings Oct. 29.
24 October 2025
···
MultiSensor AI Stock’s Wild Ride: +42% Rally on Major Deal, –50% Crash After $14M Funding

MultiSensor AI Stock’s Wild Ride: +42% Rally on Major Deal, –50% Crash After $14M Funding

MultiSensor AI shares jumped up to 100% on Oct. 23 after announcing a major U.S. deployment deal, then plunged nearly 50% the next day following news of a $14 million private share placement at $0.409 per share. As of Oct. 24 midday, the stock traded near $0.73, down 47% on the day and 32% below last year. Institutions own 82% of shares. Full-year 2024 revenue was $7.4 million with a $21.5 million net loss.
24 October 2025
···
Adverum (ADVM) Stock Skyrockets on News of Lilly’s $12.47/Share Gene Therapy Deal

Adverum (ADVM) Stock Skyrockets on News of Lilly’s $12.47/Share Gene Therapy Deal

Eli Lilly said Oct. 24 it will buy Adverum Biotechnologies for $3.56 per share plus a CVR worth up to $8.91, targeting Adverum’s lead gene therapy Ixo-vec for wet AMD. Adverum shares jumped 17% on the news but stayed well below the $12.47 maximum deal value. The agreement includes a $65 million secured loan to fund trials before closing. Adverum had warned its cash would run out by Q4 2025.
24 October 2025
···
Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Neuphoria shares plunged about 67% in after-hours trading Oct. 20 after its lead drug BNC210 failed a Phase 3 trial for social anxiety disorder. The company halted its social anxiety program, began a strategic review, and said it would cut spending. NEUP stock dropped from $15.40 to near $4.05 before rebounding to $6.70 by Oct. 24. Neuphoria reported $14.2 million in cash as of June 30 and maintains a partnership with Merck.
24 October 2025
·
Picard Medical Stock Plummets 75% on Dilution Alert — What’s Driving the Crash?

Picard Medical Stock Plummets 75% on Dilution Alert — What’s Driving the Crash?

Picard Medical stock plunged about 75% to $3.27 by mid-day Oct. 24, after hitting a 52-week high of $13.68 the previous day. The selloff followed an SEC filing authorizing up to 18 million new shares, raising dilution fears. The company recently reported 207% Q2 revenue growth and completed a $19.5 million IPO in September. Analysts cite uncertainty over future growth and dilution.
24 October 2025
·
General Dynamics Stock Rockets to Record High on Blowout Q3 Results and Defense Windfall

General Dynamics Stock Rockets to Record High on Blowout Q3 Results and Defense Windfall

General Dynamics reported Q3 2025 revenue of $12.91 billion, up 10.6% year-over-year, and EPS of $3.88, beating forecasts. Gulfstream jet deliveries rose to 39 from 28, driving a 30% jump in aerospace revenue. The company ended the quarter with a $167.7 billion backlog and won major new defense contracts. GD shares climbed to around $353 after hours, up 27% year-to-date.
24 October 2025
···
NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis announced FDA 510(k) clearance for its PENFS device to treat adult functional dyspepsia on Oct. 24, marking the first approved therapy for this condition. NRXS shares rose to $3.82 on Oct. 23 and traded higher pre-market after the news. The company recently raised $5 million and expanded insurance coverage to 53 million lives. Q2 revenue grew 46% year-over-year; analyst sentiment remains mixed.
24 October 2025
··
Bond Yields Plunge on Cooling Inflation – Fed Cuts and Stock Rally in Play?

Bond Yields Plunge on Cooling Inflation – Fed Cuts and Stock Rally in Play?

U.S. consumer inflation rose 3.0% year-on-year in September, slightly below forecasts, prompting markets to fully price in a Fed rate cut next week. The 10-year Treasury yield fell below 4% and the dollar weakened on the news. S&P 500 futures jumped about 1%, lifting stocks toward record highs. Financials outperformed, while homebuilders and utilities lagged.
24 October 2025
···
Stocks Rocket on Cooling Inflation Data; Tech Stocks & Fed Speeches in Spotlight

Stocks Rocket on Cooling Inflation Data; Tech Stocks & Fed Speeches in Spotlight

US September CPI rose 3.0% year-on-year, below the 3.1% forecast, fueling a Wall Street rally and bets on a Fed rate cut next week. Nasdaq gained 0.9%, S&P 500 rose 0.6%, and Dow added 0.3% on October 23. Philadelphia Fed manufacturing index plunged to −12.8 in October from +23.2. Oil prices spiked on new sanctions, while gold eased from record highs.
24 October 2025
···
Stocks Rally as U.S. Inflation Cools – Asia Joins Global Rally, Fed Cut Seen as Lock

Stocks Rally as U.S. Inflation Cools – Asia Joins Global Rally, Fed Cut Seen as Lock

U.S. consumer prices rose 0.3% in September, below forecasts, with core CPI up 0.2%. Wall Street futures climbed after the data; Dow E-mini futures gained 0.5%, S&P 500 E-minis 0.7%, and Nasdaq 100 E-minis 0.98%. Intel surged 8% pre-market on strong earnings, while Deckers Outdoor dropped 11.5% after cutting guidance. Fed futures now price in a 25bp rate cut at next week’s meeting.
24 October 2025
·······
Billionaire Larry Ellison’s Fortune Plummets: Oracle Share Slump Wipes Out $24B

Billionaire Larry Ellison’s Fortune Plummets: Oracle Share Slump Wipes Out $24B

Oracle shares fell 7% on Oct. 17 and nearly 5% on Oct. 20, erasing about $38 billion from Larry Ellison’s net worth. The stock closed near $280 on Oct. 23, down from September highs but still up roughly 70% year-to-date. Ellison remains the world’s second-richest person at $336–351 billion. Analysts’ price targets for Oracle range widely, with some citing risks tied to its AI rollout.
24 October 2025
··
Microsoft Stock Soars on AI and Cloud Frenzy – Analysts Eye $600+ Price Targets

Microsoft Stock Soars on AI and Cloud Frenzy – Analysts Eye $600+ Price Targets

Microsoft shares closed near $520, up 25% year-to-date, with a market cap approaching $3.8 trillion. Azure cloud revenue jumped 39% last quarter, outpacing AWS and Google Cloud. Wall Street remains bullish, with 32 of 34 analysts rating MSFT a “Buy” and a 12-month price target near $620–630. Microsoft reports Q1 FY2026 results on Oct. 29, with analysts expecting continued double-digit growth.
24 October 2025
····
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

RVPH shares closed at $0.57 on Oct 24 after a volatile month, swinging between $0.26 and $0.84. The stock surged 28% on Oct 23 following recent Phase 3 trial results for brilaroxazine and news of an upcoming FDA meeting. Reviva raised about $19 million this year to fund its CNS pipeline. Analyst targets average $6.25, implying a potential 1,000% upside.
24 October 2025
···
AMD Stock Skyrockets on AI Mega-Deals – Is $300 Next?

AMD Stock Skyrockets on AI Mega-Deals – Is $300 Next?

AMD shares jumped 34% on Oct. 6 after announcing major AI GPU deals with OpenAI and Oracle, adding $80 billion in market value. The stock is up about 80–95% year-to-date, reaching all-time highs near $238 before settling at $235 by Oct. 23. Analysts raised price targets to as high as $310. Q2 2025 revenue rose 32% to $7.69 billion, with full-year sales guidance near $33 billion.
24 October 2025
···
Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta Science shares surged over 300% in early trading Oct. 24 after announcing an expanded partnership with Anemocyte to develop off-the-shelf lentiviral vector plasmid DNA for cell therapies. The company’s lead candidate Temferon showed a 29% two-year survival rate in glioblastoma patients, more than double standard care. Net loss narrowed to €3.83M in H1 2025. Analyst targets average $22.73, far above current prices.
24 October 2025
··
Plug Power (PLUG) Stock Skyrockets 170% on Hydrogen Hype – Can It Last?

Plug Power (PLUG) Stock Skyrockets 170% on Hydrogen Hype – Can It Last?

Plug Power shares traded near $2.88 on Oct. 23, up about 170% since early September. The company secured a 1 GW electrolyzer order from Fortescue and delivered its first 10 MW unit to Galp’s Portugal project. Plug raised $370 million through warrant exercises on Oct. 8. Founder/CEO Andy Marsh will move to Executive Chair in 2026, with José Luis Crespo set to become CEO.
24 October 2025
··
1 … 1,241 1,242 1,243 1,244 1,245 … 1,330
Go toTop